Document is current

Article History

Received: 17 February 2025

Accepted: 23 March 2025

First Online: 31 May 2025

Declarations

:

: All patients provided written informed consent for their data to be used for research purposes. The study was approved by the Research and Ethics Board of Amsterdam UMC (METc 2022.0120). The study was performed in accordance with the Declaration of Helsinki.

: Not applicable.

: Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Eli-Lilly-NL, Fujifilm, Eisai, Combinostics. WF holds the Pasman chair. WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. WF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. WF is member of the steering committee of EVOKE/EVOKE+ (NovoNordisk). All funding is paid to her institution. WF is member of the steering committee of PAVE, and Think Brain Health. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain. WF is member of Supervisory Board (Raad van Toezicht) Trimbos Instituut.Evert-Ben van Veen was a paid consultant for the consent procedure and the regulation instituting the governance structure of the ABOARD Cohort. Evert-Ben van Veen was a paid consultant for the consent procedure and the regulation instituting the governance structure of the ABOARD Cohort.